Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna Inc said on Wednesday its newly appointed chief financial officer, Jorge Gomez, departed from the drugmaker after his former employer Dentsply Sirona Inc disclosed an internal probe into financial reporting.

Moderna new CFO leaves as former employer launches probe

Moderna Inc. MRNA, -2.56% said Wednesday its recently appointed chief financial officer, Jorge Gomez, has departed the company with immediate effect. The company said the move comes after the May 10 disclosure from Dentsply Sirona Inc. XRAY, -7.31% of an internal investigation into certain matters, including financial reporting.

Moderna's recently appointed CFO is out after former employer Dentsply discloses internal probe of financial reporting

CAMBRIDGE, MA / ACCESSWIRE / May 11, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that its recently appointed Chief Financial Officer, Jorge Gomez, has departed the Company, effective immediately. The announcement follows the May 10 public disclosure by Mr.

Departure of Jorge Gomez and Continuation of David Meline as Chief Financial Officer

Moderna will likely need to make a move sooner or later.

Is Moderna Wasting a Golden Opportunity?

Athersys

Amicus Therapeutics

Lexicon Pharmaceuticals

Nanobiotix SA

United Therapeutics

Verrica Pharmaceuticals Inc

The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on InvestorPlace.

7 Biotech Stocks With Key Catalysts for May

Moderna Inc (NASDAQ: MRNA) shares are trading lower by 3.15% at $131.52. Vaccine stocks are falling in sympathy with Novavax, Inc. (NASDAQ: NVAX), which reported worse-than-expected first-quarter EPS and sales results.

Why Moderna Shares Are Trading Lower Following Novavax's Earnings Report

Biogen

Novavax

UnitedHealth Group

Veru

Could these health care stocks be the remedy to investors' recent stock market pains?

Best Stocks To Buy Now? 5 Health Care Stocks In Focus

Since the news over COVID-19 has waned down so too has Moderna's share price collapsed. The company has several long-term franchises in COVID-19 along with RSV and the Flu which are entering Phase 3 trials.

Moderna's Collapse Means Massive Opportunity

Alpha and Omega Semiconductor

CF Industries Holdings

Gilead Sciences

Intrepid Potash

Mosaic

Sanderson Farms

Companies with high debt lived in a sort of paradise in 2019 to 2021. With interest rates extraordinarily low, their debt burden didn't hurt.

Now's the Time for Low-Debt Stocks to Pay Off

CAMBRIDGE, MA / ACCESSWIRE / May 9, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that that it will host its in-person Science and Technology Day for analysts and investors at 9:00 a.m. ET on Tuesday, May 17 in Boston, MA.

Moderna to Host Annual Science and Technology Day on May 17, 2022

Adobe

Alphabet

Growth stocks have gotten cheap in the market sell-off.

3 Growth Stocks That Are Screaming Buys in May

4 Bold Words From Moderna's CEO That Could Be Worth Billions

Total revenues rose to around $6.07 billion, with earnings per share standing at $8.58, marking a three-fold increase from the year-ago period when the company just started ramping up its vaccine sales.

Will Moderna's Strong Q1 Help Its Beaten Down Stock?

2 Reasons Moderna Could Dominate the Long-Term Vaccine Market

The company acknowledged that some of its projected revenue is at risk.

Why Moderna Might Make Less Money This Year Than Everyone Expects

Moderna delivered revenues of $6.1 billion and a net profit margin >60% in Q122. That's all down to Advance Purchase Agreements for SpikeVax, its COVID vaccine and only commercial product.

Moderna: Blowout Quarterly Earnings Won't Last Forever - But Q1 2022 Was Certainly One

Bristol-Myers

CVS Health

GlaxoSmithKline

Pfizer

Should investors' be looking at these health care stocks this earnings season?

5 Health Care Stocks For Your May 2022 Watchlist

Bio-Rad Laboratories

Lamb Weston Hlds

Match Group

Prologis

Molson Coors Brewing

T-Mobile US

Twitter

Vornado Realty Trust

It's always tough to predict which S&P 500 companies will beat earnings forecasts. But analysts still think you can profit from some that did.

9 Stocks That Crushed Estimates Are Still Undervalued, Analysts

Moderna delivers another billion-dollar quarter.

This Prediction From Moderna's CEO Should Eliminate Investors' Biggest Worry

COVID-19 vaccine sales are fueling the biotech's staggering growth.

Why Moderna Stock Jumped Today

Moderna Therapeutics Inc (NASDAQ:MRNA) is projecting increased vaccine sales in the second half of 2022 as it develops a “next-generation booster,” according to first-quarter results released Wednesday. Sales of the Moderna vaccine were $5.9 billion in the first quarter, and the firm projects $21 billion total in 2022.

Moderna expects vaccine sales to increase in the back half of 2022 with fall-winter booster in development

Lyft

Starbucks

Uber

Lyft, Uber, Starbucks and Moderna are all moving on earnings and they are our top stock trades for Thursday. Now, let's look at the charts.

4 Top Stock Trades for Thursday: LYFT, UBER, SBUX, MRNA

Moderna, Inc. (NASDAQ:MRNA ) Q1 2022 Results Conference Call May 4, 2022 8:00 AM ET Company Participants Lavina Talukdar - Head IR Stephane Bancel - CEO David Meline - CFO Stephen Hoge - President Paul Burton - Chief Medical Officer Conference Call Participants Salveen Richter - Goldman Sachs Matthew Harrison - Morgan Stanley Gena Wang - Barclays Michael Yee - Jefferies Tyler Van Buren - Cowen Alec Stranahan - Bank of America Joseph Stringer - Needham & Company Operator Good morning. My name is Kevin, and welcome to Moderna's First Quarter 2022 Earnings Call.

Moderna, Inc. (MRNA) CEO Stephane Bancel on Q1 2022 Results - Earnings Call Transcript

Moderna's (MRNA) Spikevax sales beat expectations. The company plans to start late-stage studies for Omicron-containing bivalent booster and seasonal flu vaccines later this year.

Moderna (MRNA) Beats on Q1 Earnings, to Start Two Late Studies

Shares moved lower despite strong earnings results from the vaccine-maker.

News for Moderna Stock (MRNA)